Abbreviated New Drug Application (ANDA) | FDA. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda. Accessed 13 Nov 2024

IPA, Focus on First Cycle Approval of ANDAs Regulatory Best Practices CONTENTS. https://www.ipa-india.org/wp-content/uploads/2021/03/forum-2021b.pdf (2021). Accessed 23 Nov 2024

Generic Drug Applications: FDA Should Take Additional Steps to Address Factors That May Affect Approval Rates in the First Review Cycle | U.S. GAO. https://www.gao.gov/products/gao-19-565. Accessed 13 Nov 2024

The Generic Drug User Fee Amendments (GDUFA III). https://accessiblemeds.org/sites/default/files/2021-10/AAM-GDUFA-III-One-Pager-10-29-2021.pdf. Accessed 23 Nov 2024

Generic Drug User Fee Amendments | FDA. https://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments. Accessed 13 Nov 2024

Chazin H, Woo J, Han J, Grosser S, Luan J. FDA’s generic drug program: decreasing time to approval and number of review cycles. Ther Innov Regul Sci. 2020;54:758–63.

Article  PubMed  Google Scholar 

Generic Drugs Program Activities Report—FY 2022 Monthly Performance | FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2022-monthly-performance. Accessed 21 Oct 2024

Activities Report of the Generic Drugs Program (FY 2019) Monthly Performance | FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/activities-report-generic-drugs-program-fy-2019-monthly-performance. Accessed 12 Nov 2024

Activities Report of the Generic Drugs Program (FY 2020) Monthly Performance | FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/activities-report-generic-drugs-program-fy-2020-monthly-performance. Accessed 12 Nov 2024

Activities Report of the Generic Drugs Program (FY 2021) Monthly Performance | FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/activities-report-generic-drugs-program-fy-2021-monthly-performance. Accessed 12 Nov 2024

Generic Drugs Program Activities Report - FY 2023 Monthly Performance | FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2023-monthly-performance. Accessed 12 Nov 2024

Hatch-Waxman Letters | FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters. Accessed 12 Nov 2024

Abbreviated New Drug Application (ANDA) | FDA. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda. Accessed 12 Nov 2024

Fda, Cder, Sollenberger, Michelle. ANDA Submissions—Content and Format Guidance for Industry Rev. 1, 2019. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-content-and-format-abbreviated-new-drug-applications. Accessed 23 Nov 2024

Abbreviated New Drug Application (ANDA) Forms and Submission Requirements | FDA. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-forms-and-submission-requirements. Accessed 12 Nov 2024

Fda, Cder. FDA Fact Sheet: What’s Involved in Reviewing and Approving Generic Drug Applications? (PDF). https://fda.report/media/99163/FDA-Fact-Sheet--What%27s-Involved-in-Reviewing-and-Approving-Generic-Drug-Applications--%28PDF%29.pdf. Accessed 23 Nov 2024

Title 21-Food and Drugs Chapter I-Food and Drug Administration, Department of Health and Human Services Subchapter D-Drugs for Human Use Part 314-Applications for FDA Approval to Market a New Drug Subpart C-Abbreviated Applications94 Content and format of an ANDA. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-C/section-314.94. Accessed 23 Oct 2024

The Generic Drug Approval Process | FDA. https://www.fda.gov/drugs/cder-conversations/generic-drug-approval-process?os=fno_journeystrueno_journeystrue0&ref=app. Accessed 14 Nov 2024

FDA. Manual of policies and procedures Center for drug evaluation and research Mapp 5200.14 rev. 1 policy and procedures office of generic drugs Filing Review of Abbreviated New Drug Applications, 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents.

FDA. Good ANDA Submission Practices Guidance for Industry, 2022. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs. Accessed 21 Oct 2024

Fda, Cder. Ogdp Manual of policies and procedures Center for drug evaluation and research Mapp 5220.3 policy and procedures Office of Generic Drugs Communicating Certain Deficiencies Identified During Filing Review of ANDAs. https://www.fda.gov/media/107774/download. Accessed 23 Nov 2024

Fda, Cder. ANDA Submissions-Amendments to Abbreviated New Drug Applications Under GDUFA Guidance for Industry, 2024. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.

ANDA Submissions - Refuse-to-Receive Standards: Questions and Answers Guidance for Industry | FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-refuse-receive-standards-questions-and-answers-guidance-industry. Accessed 30 Jul 2024

Fda, Cder. Manual of policies and procedures Center for drug evaluation and research Mapp 5220.5 Rev. 2 POLICY AND PROCEDURES OFFICE OF GENERIC DRUGS Issuance of Information Requests and/or Discipline Review Letters for Abbreviated New Drug Applications. https://www.fda.gov/media/109649/download, 2024. Accessed 23 Nov 2024

Kulkarni SB, Gaikwad VL. Common chemistry, manufacturing, and control deficiencies in abbreviated new drug applications assessed by the US Food and drug administration: Hurdle to access cost-effective medicines. J Pharmacol Toxicol Methods. 2023;123: 107295.

Article  PubMed  CAS  Google Scholar 

Liu Q, Davit BM, Cherstniakova SA, Dandamudi S, Walters JF, Lee CH, Raines KW, Ren K, Williamson LN, Conner DP. Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA. AAPS J. 2012;14:19–22.

Article  PubMed  Google Scholar 

Fermaglich LJ, Chen R, Kim CY, Chuh EE, Thomas T, Shetty D, Lee J, Young J, Fan Y. Common filing deficiencies in abbreviated new drug applications containing clinical endpoint studies. Ther Innov Regul Sci. 2019;53:81–5.

Article  PubMed  Google Scholar 

Lu D, Vivian D, Ren P, Yang Y, Zhang H, Jiang X, Stier E. Common deficiencies of in vitro binding bioequivalence (BE) studies submitted in abbreviated new drug applications (ANDAs). AAPS J. 2018. https://doi.org/10.1208/s12248-017-0182-5.

Article  PubMed  Google Scholar 

Williamson LN, Conner DP, Stier EM, Davit BM. Common bioanalytical deficiencies with bioequivalence submissions in Abbreviated New Drug Applications. Bioanalysis. 2014;6:441–5.

Article  PubMed  CAS  Google Scholar 

Chen Z, Wang Z, Shah R, Scherlitz A, Feng X, Wu L. Assessment of Manufacturing Related Deficiencies for Modified Release Tablet in Abbreviated New Drug Applications.

Li J. Common Manufacturing Related Deficiencies for Liquid Drug Products, 2022. https://www.fda.gov/media/165542/download

Nguyen J. GDUFA III Enhancement: Assessment of Solicited DMF Amendments. www.fda.gov. Accessed 2 Dec 2024

FDA Ee-Sunn (Joanne). GDUFA II update and DMF strategies to support first-cycle approvals, 2019. www.fda.gov.

Cder O/, Fda / Best Practices for Abbreviated New Drug Applications (ANDAs) in GDUFA III: Office of Pharmaceutical Quality Perspective. www.fda.gov.

Benjamin Danso C. Closing out GDUFA II-Summary of DMF Performance. www.fda.gov, 2022.

Skoda E. GDUFA II Drug Master File Update. www.fda.gov.

Pai V. Process deficiencies for ANDA’s-a dive into trends 7th Advanced GMP Workshop 2022 Indian Pharmaceutical Alliance. www.fda.gov.

FDA. FDA Perspectives: Common Deficiences in Abbreviated New Drug Applications (Part 4). In: Pharmaceutical Technology. https://www.pharmtech.com/view/fda-perspectives-common-deficiences-abbreviated-new-drug-applications-part-4, 2011. Accessed 13 Nov 2024

Yoko Aoi, FDA Perspectives: Common Deficiencies in Abbreviated New Drug Applications: Part 3—Control of the Drug Product and Stability. In: Pharmaceutical Technology. https://www.pharmtech.com/view/fda-perspectives-common-deficiencies-abbreviated-new-drug-applications-part-3-control-drug-product-a, 2011. Accessed 13 Nov 2024

Peterson C, Jung HA. Current Trends and Best Practices in ANDA Labeling. www.fda.gov. Accessed 1 Dec 2024

Lillie Golson C, Director D. Generic Drug Labeling: Strategies for Providing High-Quality Submissions, 2017.

Fda, Cder. CDER Approval Package for: CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: ANDA212184Orig1s000 CONTENTS. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212184Orig1s000Approv.pdf, 2021. Accessed 21 Oct 2024

Fda, Cder. Center For Drug Evaluation And Research Administrative And Correspondence Documents. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212184Orig1s000AdminCorres.pdf. Accessed 23 Nov 2024

Fda, Cder. Center For Drug Evaluation And Research Anda 212184 Labeling Review(S). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/212184Orig1s000lblRev.pdf. Accessed 21 Oct 2024

Center For Drug Evaluation And Research Approval Package for ANDA 203753. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/203753Orig1s000ChemR.pdf. Accessed 18 Jan 2025

Fda CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for ANDA 211097. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/211097Orig1s000.pdf. Accessed 18 Jan 2025

Fda, Cder. Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA Guidance for Industry, 2024. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs.

FDA ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA | FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/anda-submissions-amendments-abbreviated-new-drug-applications-under-gdufa. Accessed 20 Oct 2024

Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors | FDA. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-considerations-container-labels-and-carton-labeling-design-minimize-medication-errors. Accessed 14 Nov 2024

Ensor, Frederick Drug Master Files Guidance for Industry DRAFT GUIDANCE. https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics-guidances. Accessed 1 Dec 2024

FDA Acceptability of Draft Labeling to Support ANDA Approval Guidance for Industry. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

Michael Flores L Guidance for Industry ANDA Submissions-Amendments and Easily Correctable Deficiencies Under GDUFA. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed 1 Dec 2024